Publication at Faculty of Science, Third Faculty of Medicine |
2009
Abstract
This review describes all nine currently available FDA-approved protease inhibitors, discusses their pharmacokinetic properties, off-target activities, side-effects, and resistance profiles. The compounds in the various stages of clinical development are also introduced, as well as alternative approaches, aiming at other functional domains of HIV PR.
The potential of these novel compounds to open new way to the rational drug design of human viruses is critically assessed.